Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (20672)	5/13/1998 11:58:00 AM
From: bob zagorin	Read Replies (2) \| Respond to of 32384

apologies if posted before. this is from Lehman update on ASCO schedule. Ligand (LGND, 14 1/4, 1-Buy) Ligand had 4 abstracts accepted by ASCO. The first is preclinical data showing that receptor selective retinoids can inhibit tumor cell lines. The second and third are phase I/II dose ranging trials using oral LGD1550 (May 18- 1:00PM-5:00PM Poster session) in patients with advanced cancer to evaluate pharmacokinetics, safety, clinical tolerance and attempt to determine the maximally tolerated dose. The fourth abstract is a phase II trial using oral LGD1057 in AIDS related Kaposi sarcoma. An interim analysis of 66 patients was completed. 38 patients received at least 16 weeks of drug and were included in the analysis. Partial responses were seen in 14 patients (37%), stable disease in 15 (39%) and progressive disease in 4 (11%). 11 patients withdrew from the study due to adverse events, which included grade 3 or 4 elevations of triglycerides (5 pts.), headaches (8 pts.) and skin problems. Cholesterol and triglyceride levels rose significantly from a mean baseline cholesterol level of 187 to 277 and a mean baseline triglyceride level from 240 to 788.

To: John O'Neill who wrote (20672)	5/13/1998 12:28:00 PM
From: Henry Niman	Respond to of 32384

JO, Evista is a SERM as is Tamoxifen, Droloxifene, CP-366,156, and TSE424 (see home.att.net for details). In animal models Targretin, Panretin, and LGD1268 synergize with Tamoxifen and Evista for treatment and prevention of breast cancer. The government is sponsoring two clinical trials combining Panretin with Tamoxifen to treat breast cancer (in humans). Initial data from one of the trials will be presented next week at ASCO: Message 4436086 LGND has a research program with LLY to explore combining rexinoids (like Targretin, LGD1268, LGD1324) with SERMS (like Evista or their 2nd generation compound) to treat (and prevent?) cancer (like breast cancer).